3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer

Phase 4 Completed 383 enrolled The University of Texas Health Science Center at San Antonio National Cancer Institute (NCI) · collab National Institutes of Health (NIH) · collab

RandomizedParallel-groupTriple-blindScreening

Summary

The investigators will propose a novel method to improve prostate cancer screening with PSA, using a 3-month treatment with finasteride, a drug used to treat Benign Prostatic Hyperplasia (BPH) and proven to reduce a man's risk of developing prostate cancer. The investigators will also examine three additional promising tests that may further improve diagnosis of prostate cancer.

Timeline

Start: 2011-02
Primary completion: 2016-11
Completion: 2017-01

Publications

Hernandez J, Gelfond J, Goros M, Liss MA, Liang Y, Ankerst D, Thompson IM Jr, Leach RJ. The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial. PLoS One. 2018 Oct 9;13(10):e0204823. doi: 10.1371/journal.pone.0204823. eCollection 2018.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Finasteride	Small molecule	5 mg	Oral

3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications